Health & Environmental Research Online (HERO)


Print Feedback Export to File
7084272 
Journal Article 
Significant systemic therapeutic effects of high-LET immunoradiation by (212)pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice 
Tan, Z; Chen, P; Schneider, N; Glover, S; Cui, L; Torgue, J; Rixe, O; Spitz, HB; Dong, Z; , 
2012 
Yes 
International Journal of Oncology
ISSN: 1019-6439
EISSN: 1791-2423 
SPANDIDOS PUBL LTD 
ATHENS 
40 
6 
1881-1888 
English 
22322558 
WOS:000303699900017 
The purpose of this study was to determine therapeutic effects and systemic toxicity of Pb-212-trastuzumab in an orthotopic model of human prostate cancer cells in nude mice. TCMC-Trastuzumab was radiolabeled with Pb-212. The Pb-212-trastuzumab generated from the procedure was intact and had high binding affinity with a dissociation constant (of 3.9+/-0.99 nM. PC-3MM2 cells, which expressed a lower level of HER2 both in culture and in tumors, were used in therapy studies. A single intravenous injection of Pb-212-trastuzumab reduced tumor growth by 60-80%, reduced aortic lymph node metastasis, and prolonged the survival of tumor-bearing mice. Treatment with Pb-212-trastuzumab did not cause significant changes in body weight, serum glutamic pyruvic transaminase (SGPT), blood urea nitrogen (BUN), hematological profiles, and histological morphology of several major organs of tumor-bearing mice. These findings suggest that a systemic delivery of Pb-212-trastuzumab could be an effective modality for management of advanced human prostate cancer.